Observational studyTechnology in cancer research & treatment
Efficacy and Safety of Simultaneous Integrated Boost Followed by Selective Sequential Boost Radiotherapy for Spinal Metastases: A Single-Arm Retrospective Study.
Observational study in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study evaluated the clinical efficacy and safety of simultaneous integrated boost (SIB) followed by selective sequential boost radiotherapy (RT) in patients with spinal metastases (SM) and explored the protocol's potential for dosimetric optimization.MethodsIn this retrospective study, 34 consecutive patients with SM underwent SIB followed by selective sequential boost RT at Peking University Third Hospital between July 2021 and December 2024. Prescribed doses were 30 Gy in 10 fractions to the planning target volume (PTV), with dose escalation to the boost planning target volume (PTV_boost) of either 40 Gy in 10 fractions or 48 Gy in 12 fractions. The primary endpoints included pain relief (Numerical Rating Scale), neurological improvement (Frankel Grade), and adverse events (RTOG/EORTC criteria). Secondary endpoints comprised local control rate (LCR), evaluated by MRI or CT, and cancer-specific survival (CSS).ResultsThe median follow-up was 9.9 months (range: 3.4-44.3 months), and 26 of 34 patients reported pain before treatment; of these, 84.6% (22/26) experienced pain relief (30.8% complete, 53.8% partial). Neurological function improved in 72.7% (16/22) of affected patients, with complete improvement in 27.3% and partial improvement in 45.5%. The majority of adverse events were grade 1-2 and resolved following appropriate symptomatic management. Kaplan-Meier analysis showed LCRs of 97.1%, 90.2%, 90.2%, and 90.2% at 3, 6, 12, and 24 months, respectively, and CSS rates of 97.0%, 97.0%, 87.0%, and 56.8% at the corresponding intervals.ConclusionsIndividualized dose-escalation RT may be a promising treatment for SM, potentially delivering significant pain relief, neurological recovery, and durable local tumor control, all while maintaining strict dosimetric constraints for organs at risk. Further prospective multicenter trials are essential to validate its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.